Why the study?
Does terbutaline prevent hypokalaemic paralysis attacks in a patient with Andersen's syndrome?
Does terbutaline prevent hypokalaemic paralysis attacks in a patient with Andersen's syndrome?
Terbutaline may provide temporary symptomatic relief of hypokalaemic paralysis in Andersen's syndrome, but does not eliminate the risk of fatal respiratory arrest.
Answers are grounded in this paper and cite their sources.
May support short-term terbutaline for hypokalemic attacks in Andersen syndrome; leaves open prevention of fatal respiratory arrest.
In this paper a follow‐up is presented of a case report initially described by Andersen in 1971. The patient presented with a syndrome including elements of familial periodic paralysis with hypokalaemia, long QT syndrome, ventricular ectopy, myopathy with fibre‐type disproportion and dysmorphic features resembling Treacher Collins' syndrome. The main symptom was hypokalaemic paralysis. The episodes were accompanied by a lowered intracellular potassium content and an increase in intracellular sodium. Treatment with terbutaline, a Na/K‐ATPase‐stimulating drug, resulted in attack‐free periods of approximately 9 months, after which the attacks reoccurred. The patient suffered severe attacks whenever treatment with terbutaline was stopped. The patient experienced two attacks of respiratory arrest, the second being fatal.
No takes yet. Share an insight, caveat, or question.
Djurhuus et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: